Catalyst Event

Pfizer Inc (PFE) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

3/17/2026, 12:00:00 AM

OtherSentiment: Positive

Announced positive topline results on March 17, 2026, from the Phase 2 study of atirmociclib, a next-generation CDK4 inhibitor, for second-line metastatic breast cancer.

Korean Translation

2026년 3월 17일, 2차 전이성 유방암 치료를 위한 차세대 CDK4 억제제 아티르모시클립(atirmociclib)의 2상 임상에서 긍정적인 탑라인 결과를 발표함.

Related Recent Events

View Full Timeline